ORPHA:83312
Rickettsialpox
Publications
426
71th percentile
Trials
0
Interventional, condition-specific
Researchers
793
Distinct authors in sample
Gene link
—
Readiness
1/6
Stages with a signal
Clinical definition (Orphanet)
A rare, acquired, self-limiting, infectious disease due to the mite-borne bacteria Rickettsia akari characterized by an asymptomatic, 0.5 to 2 cm in diameter papulovesicle that typically ulcerates and forms an eschar, followed by a generalized papulovesicular rash associating variable constitutional symptoms, such as localized lymphadenopathy, fever, malaise, and headaches. Additonal symptoms may include diaphoresis, myalgia and, less frequently, rhinorrhea, pharyngitis, nausea, vomiting, , conjunctival hyperemia, and abdominal pain. Systemic symptoms resolve within 6-10 days.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0019360
- UMLS:C0035597
Additional Mondo synonyms (1)
vesicular rickettsiosis
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
1/6 stages with a signal
Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
426 matched papers (130 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
426
426 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
426 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
130 in the last 10 years · medium confidence · 71th percentile (publications denominator)
Phrase hits: 426 · MeSH hits: 0
Who's working on it?
793
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Paddock CD12 papers · 2021
Rickettsial Zoonoses Branch, Mailstop G-13, Centers for Disease Control and Prevention, 1600 Clifton Rd., Atlanta, GA 30333, USA.
Papers in Europe PMC - 02Walker DH8 papers · 2025
The University of Texas Medical Branch at Galveston, Galveston, Texas 77555-0609, USA; email: absahni@utmb.edu , rofang@utmb.edu , sksahni@utmb.edu , dwalker@utmb.edu.
Papers in Europe PMC - 03Comer JA7 papers · 2007
Viral and Rickettsial Zoonoses Branch, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA. jnc0@cdc.gov
Papers in Europe PMC - 04Childs JE5 papers · 2007
Department of Epidemiology and Public Health and Center for Eco-Epidemiology, Yale University School of Medicine, 60 College Street, P.O. Box 208034 New Haven, CT 06520-8034, USA. jamesechilds@comcast.net
Papers in Europe PMC - 05Raoult D5 papers · 2012Papers in Europe PMC
- 06Zavala-Castro JE5 papers · 2009
Facultad de Medicina, Unidad Interinstitucional de Investigación Clínica y Epidemiológica, Universidad Autónoma de Yucatán, Mérida, Yucatán, Mexico. zcastro@uady.mx
Papers in Europe PMC - 07Zavala-Velázquez JE5 papers · 2009Papers in Europe PMC
- 08Guo XG4 papers · 2025
Vector Laboratory, Institute of Pathogens and Vectors, Yunnan Provincial Key Laboratory for Zoonosis Control and Prevention, Dali University, Dali, China.
Papers in Europe PMC - 09Jin DC4 papers · 2025
Institute of Entomology, Guizhou University, and the Provincial Key Laboratory for Agricultural Pest Management in Mountainous Region, Guiyang, China.
Papers in Europe PMC - 10Song WY4 papers · 2025
Vector Laboratory, Institute of Pathogens and Vectors, Yunnan Provincial Key Laboratory for Zoonosis Control and Prevention, Dali University, Dali, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
medium confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Rickettsialpox" OR "vesicular rickettsiosis"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Rickettsialpox" OR "vesicular rickettsiosis"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is short or not clearly distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T02:33:23.607Z